Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately...

Overview

Journal Clin Diabetes

Specialty Endocrinology

Date 2018 Apr 25

PMID 29686454

Citations 8

Authors

Carol H Wysham

Carlos Campos

Davida Kruger

Affiliations

Soon will be listed here.

Abstract

Novel co-formulations of basal insulin analogs and glucagon-like peptide-1 (GLP-1) receptor agonists have provided new options for patients with type 2 diabetes who are not reaching recommended glycemic targets. The components of currently available co-formulations (insulin degludec/ liraglutide [IDegLira,] and insulin glargine U100/lixisenatide [iGlarLixi]) act synergistically to address multiple pathophysiologic defects while minimizing the side effects associated with either component when used alone. In Europe, these products are approved for use in patients on regimens of one or more oral antidiabetic drugs; in the United States, they are indicated for use as an adjunct to diet and exercise in patients with type 2 diabetes inadequately controlled with either basal insulin or their respective GLP-1 receptor agonist component. This article reviews key clinical trials in which these products were initiated in insulin-naive patients and describes how they can be safely and effectively titrated in clinical practice.

Citing Articles

Open questions on basal insulin therapy in T2D: a Delphi consensus.

Buzzetti R, Candido R, Esposito K, Giaccari A, Mannucci E, Nicolucci A Acta Diabetol. 2024; 61(10):1267-1281.

PMID: 38767675 PMC: 11486792. DOI: 10.1007/s00592-024-02285-2.

Efficacy and safety of once-weekly basal insulin versus once-daily basal insulin in patients with type 2 diabetes: A systematic review and meta-analysis.

Wang X, Xiao W, Liang Z, Li S, Tang Q Medicine (Baltimore). 2024; 102(52):e36308.

PMID: 38206709 PMC: 10754560. DOI: 10.1097/MD.0000000000036308.

Liraglutide in Combination with Insulin Has a Superior Therapeutic Effect to Either Alone on Fracture Healing in Diabetic Rats.

Liu H, Tian F, Hu Y, Ping S, Zhang L Diabetes Metab Syndr Obes. 2023; 16:1235-1245.

PMID: 37151908 PMC: 10155808. DOI: 10.2147/DMSO.S404392.

A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.

Jiang Y, Liu R, Xuan J, Lin S, Zheng Q, Pang J Clin Drug Investig. 2023; 43(4):251-263.

PMID: 36943659 DOI: 10.1007/s40261-023-01255-w.

Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.

Hanefeld M, Fleischmann H, Siegmund T, Seufert J Diabetes Ther. 2020; 11(8):1645-1666.

PMID: 32564335 PMC: 7376805. DOI: 10.1007/s13300-020-00855-5.

References

Menke A, Casagrande S, Geiss L, Cowie C . Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012. JAMA. 2015; 314(10):1021-9. DOI: 10.1001/jama.2015.10029. View

Kapitza C, Bode B, Ingwersen S, Vestergard Jacobsen L, Poulsen P . Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. J Clin Pharmacol. 2015; 55(12):1369-77. DOI: 10.1002/jcph.549. View

Bailey C . Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia. Int J Clin Pract. 2016; 70(12):988-995. DOI: 10.1111/ijcp.12906. View

Nakar S, Yitzhaki G, Rosenberg R, Vinker S . Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications. 2007; 21(4):220-6. DOI: 10.1016/j.jdiacomp.2006.02.004. View

Peyrot M, Rubin R, Lauritzen T, Skovlund S, Snoek F, Matthews D . Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28(11):2673-9. DOI: 10.2337/diacare.28.11.2673. View

Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A . Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005; 28(4):950-5. DOI: 10.2337/diacare.28.4.950. View

Vilsboll T, Vora J, Jarlov H, Kvist K, Blonde L . Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Clin Drug Investig. 2016; 36(4):293-303. PMC: 4801992. DOI: 10.1007/s40261-016-0376-0. View

Kruger D, LaRue S, Estepa P . Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes. 2015; 8:49-56. PMC: 4303400. DOI: 10.2147/DMSO.S71923. View

Harris S, Mamdani M, Galbo-Jorgensen C, Bogelund M, Gundgaard J, Groleau D . The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can J Diabetes. 2014; 38(1):45-52. DOI: 10.1016/j.jcjd.2013.09.001. View

10.

Ratner R, Gough S, Mathieu C, Del Prato S, Bode B, Mersebach H . Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2012; 15(2):175-84. PMC: 3752969. DOI: 10.1111/dom.12032. View

11.

Aroda V, Rosenstock J, Wysham C, Unger J, Bellido D, Gonzalez-Galvez G . Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016; 39(11):1972-1980. DOI: 10.2337/dc16-1495. View

12.

Khunti K, Damci T, Meneghini L, Pan C, Yale J . Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab. 2012; 14(7):654-61. DOI: 10.1111/j.1463-1326.2012.01602.x. View

13.

Oguz A, Benroubi M, Brismar K, Melo P, Morar C, Cleall S . Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Curr Med Res Opin. 2013; 29(8):911-20. DOI: 10.1185/03007995.2013.803053. View

14.

Linjawi S, Bode B, Chaykin L, Courreges J, Handelsman Y, Lehmann L . The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2016; 8(1):101-114. PMC: 5306117. DOI: 10.1007/s13300-016-0218-3. View

15.

Phillips L, Branch W, COOK C, Doyle J, Gallina D, Miller C . Clinical inertia. Ann Intern Med. 2001; 135(9):825-34. DOI: 10.7326/0003-4819-135-9-200111060-00012. View

16.

Ziemer D, Miller C, Rhee M, Doyle J, Watkins Jr C, Cook C . Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005; 31(4):564-71. DOI: 10.1177/0145721705279050. View

17.

Patrick A, Fischer M, Choudhry N, Shrank W, Seeger J, Liu J . Trends in insulin initiation and treatment intensification among patients with type 2 diabetes. J Gen Intern Med. 2013; 29(2):320-7. PMC: 3912271. DOI: 10.1007/s11606-013-2643-6. View

18.

Osataphan S, Chalermchai T, Ngaosuwan K . Clinical inertia causing new or progression of diabetic retinopathy in type 2 diabetes: A retrospective cohort study. J Diabetes. 2016; 9(3):267-274. DOI: 10.1111/1753-0407.12410. View

19.

Khunti K, Wolden M, Thorsted B, Andersen M, Davies M . Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013; 36(11):3411-7. PMC: 3816889. DOI: 10.2337/dc13-0331. View

20.

Zoungas S, Patel A, Chalmers J, de Galan B, Li Q, Billot L . Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363(15):1410-8. DOI: 10.1056/NEJMoa1003795. View